Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience

RDF 

 
This item is provided by the institution :
Hellenic Gastroenterologiki Company
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience (EN)

Yakoob, Rafie; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
John, Anil K.; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Thandassery, Ragesh Babu; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Abdel Rahman, Mohamed Osman; Department of Biochemistry Hamad General Hospital, Doha Qatar
Derbala, Moutaz F.; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Wani, Hamidulla; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Al Kaabi, Saad; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Al Mohannadi, Muneera J.; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Sharma, Manik; Division of Gastroenterology and Hepatology, Department of Medicine, Hamad General Hospital, Doha Qatar
Al Bozom, Issam; Department of Laboratory Medicine and Pathology Hamad General Hospital, Doha Qatar

Background The aim of this study was to compare noninvasive biomarkers, FibroTest and ActiTest in predicting fibrosis stage and inflammation grade in chronic hepatitis C (CHC) patients with liver biopsy (LB).Methods In 107 patients with CHC, levels of six serum biomarkers (alanine aminotransferase, γ-glutamyl transpeptidase, total bilirubin, haptoglobin, apolipoprotein, α-2 macroglobulin) were determined at the time of LB. LB was evaluated by Metavir score for fibrosis and inflammation. Voluntary blood donors (n=106) were taken as controls for the study.Results Fibrosis estimated by Fibrotest was significantly higher in patients compared to control group. The observed area under the receiver operating characteristic curve (AUROC) for advanced fibrosis (F3, F4) adjusted according to the observed difference between advanced and non-advanced fibrosis prevalence (DANA) was 0.80 (0.69-0.88) and the AUROC for cirrhosis (F4) was 0.94 (0.86-0.98). ActiTest AUROC for moderate to severe activity (A2A3) was 0.72 (0.61-0.81), and for severe activity (A3) was 0.88 (0.78-0.93). The diagnostic values in the group of good quality biopsy (n=41) showed Fibrotest AUROC (DANA-adjusted): for advanced fibrosis 0.90 (0.72-0.99); for cirrhosis 0.93 (0.76-0.98); and ActiTest AUROC: for moderate/severe activity 0.86 (0.67-0.94); and for severe activity 0.90 (0.76-0.93). There was good concordance between FibroTest and LB (with discordance for two or more stages in <20% for advanced fibrosis and <10% for cirrhosis) and between ActiTest and LB. Specificity for FibroTest and ActiTest in the control population were 95% and 100% respectively.Conclusions Fibrotest and ActiTest had high observed and standardized diagnostic values forpredicting fibrosis and activity respectively.Keywords Liver biopsy, ActiTest, Fibrotest, hepatitis C virusAnn Gastroenterol 2015; 28 (2): 265-270 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2015-03-31


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 28, No 2 (2015); 265 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)